SB-649868: Difference between revisions
No edit summary |
m moved SB649868 to SB-649,868: easier to read, standard format |
(No difference)
| |
Revision as of 23:59, 6 October 2008
SB-649,868 is an orexin receptor antagonist in development by GlaxoSmithKline. Currently in Phase 2 development, this drug for sleep disorders is one of two such compounds currently in development, the other being Actelion's ACT-078573.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |